West Pharmaceutical Servs Analyst Ratings
West Pharmaceutical Servs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 7.02% | Keybanc | $385 → $415 | Maintains | Overweight |
| 07/28/2023 | -0.71% | Keybanc | $375 → $385 | Maintains | Overweight |
| 07/17/2023 | 8.31% | Stephens & Co. | $400 → $420 | Maintains | Overweight |
| 06/16/2023 | 4.44% | B of A Securities | $390 → $405 | Upgrades | Neutral → Buy |
| 04/11/2023 | 3.15% | Stephens & Co. | $330 → $400 | Upgrades | Equal-Weight → Overweight |
| 02/17/2023 | -3.29% | Keybanc | $315 → $375 | Maintains | Overweight |
| 12/14/2022 | -35.53% | Deutsche Bank | → $250 | Initiates Coverage On | → Hold |
| 12/02/2022 | -18.77% | Keybanc | $350 → $315 | Maintains | Overweight |
| 11/30/2022 | -35.53% | UBS | → $250 | Initiates Coverage On | → Neutral |
| 10/28/2022 | -35.53% | B of A Securities | $385 → $250 | Downgrades | Buy → Neutral |
| 10/28/2022 | -9.74% | Keybanc | $400 → $350 | Maintains | Overweight |
| 07/29/2022 | -11.03% | Stephens & Co. | $330 → $345 | Maintains | Equal-Weight |
| 04/29/2022 | 5.73% | B of A Securities | $475 → $410 | Maintains | Buy |
| 04/29/2022 | 3.15% | Keybanc | $475 → $400 | Maintains | Overweight |
| 09/15/2021 | 32.81% | B of A Securities | $450 → $515 | Maintains | Buy |
| 07/30/2021 | 3.15% | Stephens & Co. | $360 → $400 | Maintains | Equal-Weight |
| 07/30/2021 | 22.5% | Keybanc | $350 → $475 | Maintains | Overweight |
| 04/30/2021 | -12.32% | Stephens & Co. | $315 → $340 | Maintains | Equal-Weight |
| 02/19/2021 | -18.77% | Stephens & Co. | $300 → $315 | Maintains | Equal-Weight |
| 11/10/2020 | -9.74% | Keybanc | → $350 | Initiates Coverage On | → Overweight |
| 10/14/2020 | -22.63% | Stephens & Co. | → $300 | Initiates Coverage On | → Equal-Weight |
| 04/24/2020 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 12/12/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 07/26/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 05/01/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 04/23/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月21日 | 7.02% | KeyBanc | $385→$415 | 维护 | 超重 |
| 07/28/2023 | -0.71% | KeyBanc | $375→$385 | 维护 | 超重 |
| 07/17/2023 | 8.31% | 斯蒂芬斯公司 | $400→$420 | 维护 | 超重 |
| 06/16/2023 | 4.44% | B of A证券 | $390→$405 | 升级 | 中性→购买 |
| 04/11/2023 | 3.15% | 斯蒂芬斯公司 | $330→$400 | 升级 | 等重→超重 |
| 02/17/2023 | -3.29% | KeyBanc | $315→$375 | 维护 | 超重 |
| 2022年12月14日 | -35.53% | 德意志银行 | →$250 | 开始承保 | →保留 |
| 12/02/2022 | -18.77% | KeyBanc | $350→$315 | 维护 | 超重 |
| 2022年11月30日 | -35.53% | 瑞银集团 | →$250 | 开始承保 | →中性 |
| 10/28/2022 | -35.53% | B of A证券 | $385→$250 | 评级下调 | 购买→中性 |
| 10/28/2022 | -9.74% | KeyBanc | $400→$350 | 维护 | 超重 |
| 07/29/2022 | -11.03% | 斯蒂芬斯公司 | $330→$345 | 维护 | 等重 |
| 04/29/2022 | 5.73% | B of A证券 | $475→$410 | 维护 | 买 |
| 04/29/2022 | 3.15% | KeyBanc | $475→$400 | 维护 | 超重 |
| 2021/09/15 | 32.81% | B of A证券 | $450→$515 | 维护 | 买 |
| 07/30/2021 | 3.15% | 斯蒂芬斯公司 | $360→$400 | 维护 | 等重 |
| 07/30/2021 | 22.5% | KeyBanc | $350→$475 | 维护 | 超重 |
| 04/30/2021 | -12.32% | 斯蒂芬斯公司 | $315→$340 | 维护 | 等重 |
| 02/19/2021 | -18.77% | 斯蒂芬斯公司 | $300→$315 | 维护 | 等重 |
| 11/10/2020 | -9.74% | KeyBanc | →$350 | 开始承保 | →超重 |
| 10/14/2020 | -22.63% | 斯蒂芬斯公司 | →$300 | 开始承保 | →等重 |
| 04/24/2020 | - | B of A证券 | 升级 | 表现不佳的→中性 | |
| 2019年12月12日 | - | B of A证券 | 评级下调 | 中性→表现不佳 | |
| 2019年07月26日 | - | B of A证券 | 升级 | 表现不佳的→中性 | |
| 2019年05月01日 | - | 杰富瑞 | 评级下调 | 购买→Hold | |
| 2019年04月23日 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 |
What is the target price for West Pharmaceutical Servs (WST)?
西部药业Serv(WST)的目标价格是多少？
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Keybanc on August 21, 2023. The analyst firm set a price target for $415.00 expecting WST to rise to within 12 months (a possible 7.02% upside). 11 analyst firms have reported ratings in the last year.
Keybanc于2023年8月21日报道了West Pharmtics Serv(纽约证券交易所代码：WST)的最新目标价。这家分析公司将目标价定为415.00美元，预计美国西部夏令时将在12个月内上涨(可能上涨7.02%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
西部药业Serv(WST)的最新分析师评级是多少？
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Keybanc, and West Pharmaceutical Servs maintained their overweight rating.
对West Pharmtics Serv(纽约证券交易所代码：WST)的最新分析师评级是由Keybanc提供的，West Pharmtics Serv维持其增持评级。
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
下一次分析师对西方制药服务公司(WST)的评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析师们在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与West Pharmtics Serv的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。对West Pharmtics Serv的最后一次评级是在2023年8月21日提交的，所以你应该预计下一次评级将在2024年8月21日左右的某个时候提供。
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
分析师对西方制药服务公司(WST)的评级正确吗？
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $385.00 to $415.00. The current price West Pharmaceutical Servs (WST) is trading at is $387.77, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的西方制药服务公司(WST)的评级保持不变，目标价在385.00美元至415.00美元之间。西方医药公司目前的交易价格为387.77美元，在分析师的预测范围内。